Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines

By Josh Enomoto, InvestorPlace Contributor

CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.

CytomX Therapeutics (CTMX) Stock Jumps 50% on Moderna Deal

By Josh Enomoto, InvestorPlace Contributor

CytomX Therapeutics announced a licensing deal with Moderna, which may supercharge the underlying ambitions of CTMX stock.

The 7 Best Stocks Under $15 to Buy Now

By Josh Enomoto, InvestorPlace Contributor

Undervalued and underappreciated, the best stocks under $15 have the potential to deliver outsized returns over the medium to long term.

What Meta Platforms’ $414 Million E.U. Fine Means for META Stock

By Josh Enomoto, InvestorPlace Contributor

Regulators from the E.U. imposed a $414 million fine on Meta Platforms, creating significant challenges for META stock.

Vimeo (VMEO) Stock Falls on Plans to Lay Off 11% of Staff

By Josh Enomoto, InvestorPlace Contributor

Vimeo recently announced layoffs that will impact 11% of its workforce, raising major concerns over embattled VMEO stock.

Load More